Company intelligence / Profile preview
Livzon Pharmaceutical Group Inc.
Zhuhai, Guangdong, Chinaen.livzon.com.cn ↗
- Ownership
- Private
- Employees
- ~9067
- Development stage
- Commercial
01
Overview
Livzon has multiple approved products across various therapeutic areas and a robust pipeline with several products in late-stage development. Recent approvals include Cetrorelix Acetate for Injection by the US FDA in 2024 and Triptorelin Acetate Microspheres for Injection for endometriosis.
- Therapeutic areas
- GastroenterologyMetabolic DisordersImmunologyWomen's HealthOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesBiosimilarsSynthetic peptidesHormonesGrowth factorsMonoclonal antibodiesMicrospheresSustained-release formulations
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
TYK MedicinesBright Peak Therapeutics
Beyond the preview
Go deeper on Livzon Pharmaceutical Group Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Livzon Pharmaceutical Group Inc..